WHAT IS THE OREGON/CIBA-GEIGY/BCR-ABL TESTING ABOUT?
This is described in Nature Medicineat: . The abstract of this article is at: . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Crg Zimmermann & Nicholas B. Lydon, Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland. Correspondence should be addressed to B.J.Druker. The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this co
